George Perry to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications George Perry has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.322
-
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit. Ageing Res Rev. 2024 Aug; 99:102348.
Score: 0.140
-
Making the Case for Accelerated Withdrawal of Aducanumab. J Alzheimers Dis. 2022; 87(3):1003-1007.
Score: 0.119
-
Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res. 2012 Nov; 43(8):694-8.
Score: 0.063